This episode of EASL Studio on Steatotic Liver Disease (SLD) will focus on critical advancements in the field. Key topics will include the development of early detection healthcare pathways, the evolving role of biomarkers in diagnosing and monitoring the disease, and the transformative impact of the first drug approval on the treatment landscape. This discussion aims to provide valuable insights into how these advancements are shaping the future of SLD management.
Moderator: Aleksander Krag
Faculty: Michelle Long (Novo Nordisk representative), Salvador Augustin (Boehringer Ingelheim)
This EASL Studio is supported by Boehringer Ingelheim and Novo Nordisk.
Related episodes:
EASL Studio at the Congress 2024: SLD nomenclature: Need for refinement?
EASL Studio at the Congress 2024: MASLD anno 2024: A rapidly changing landscape
EASL Studio S6E1: Do we solve MASLD by treating obesity?
EASL Studio S5E7: Why bother with diet and exercise when an injection will suffice?
EASL Studio S5E2: Are 30% of the global population sick? A critical view on Steatotic Liver Disease and care pathways
EASL Studio from EASL Congress 2023: Steatotic liver disease global consensus to change nomenclature
EASL Studio S4E8: The central role of alcohol and food policies on liver health